drugset / Trial / NCT05192304
Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia
Phase 1
Unknown
62 enrolled
Jiangsu Kanion Pharmaceutical Co., Ltd
Shanghai Mental Health Center · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase Ib clinical study of TPN672 maleate in patients with schizophrenia
Timeline
- Start
- 2022-02-01
- Primary completion
- 2023-03-01
- Completion
- 2024-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TPN-672 | Unknown | 0.2 mg | — |
| Subject | TPN-672 | Unknown | 0.3 mg | — |
| Subject | TPN-672 | Unknown | 0.4 mg | — |
| Subject | TPN-672 | Unknown | 0.5 mg | — |
| Subject | TPN-672 | Unknown | 0.6 mg | — |
| Subject | TPN-672 | Unknown | 0.7 mg | — |